Up-regulation of ITCH is associated with down-regulation of LATS1 during tumorigenesis and progression of cervical squamous cell carcinoma Abstract Purpose: The molecular basis for the normal cervical squamous epithelium advance to cervical intraepithelial neoplasia (CIN I, CIN II, CIN III) and ultimately to invasive carcinoma has not yet been defined. We explored the abnormal expression of ITCH (AIP4) and its degrading substrate Large Tumor Suppressor 1 (LATS1) in CINs and cervical cancers, which might disrupt the normal differentiation of the cervical epithelia and contribute to the tumorigenesis of the cervix.
Cervical cancer is one of the leading causes of death worldwide in women, and is especially prevalent in developing countries [1] . Cervical intraepithelial neoplasia (CIN) may be the premalignant transformation and abnormal proliferation of squamous cells on the surface of the cervix. Depending on the severity of the changes in the abnormal cells, there are three grades of CIN: mild (CIN I), moderate (CIN II), and severe (CIN III). Mild CIN usually returns to a normal state, whereas severe CIN may progress to cervical cancer if left untreated. Recently, pathologists combined CIN II and CIN III into a single grade, CIN II/III. The causes of cervical cancer are closely related to the persistent infection of high-risk human papillomavirus (HR-HPV) [2, 3] ; however, other factors, such as chronic inflammation [4] [5] [6] [7] , abnormal gene expression [8] , ubiquitin-mediated degradation disorders [9] [10] [11] and aberrant differentiation, may also be involved [12, 13] . To date, the exact molecular basis required for normal cervical squamous epithelial cells to advance to neoplasia, and then invasive carcinoma, has not been fully described.
The Large Tumor Suppressor (LATS) family of human tumor suppressors, which include LATS 1 and 2, has been shown to be important in maintaining cellular homeostasis [14] . Because of their high degree of homology and significant overlap in function, LATS1 and LATS2 comprise a unique signaling family within the cell, and they are both identified within the Hippo-LATS pathway as vital players [15, 16] . LATS1 and LATS2 suppress tumor growth by inducing G2-M and G 1 -S cell-cycle arrest, respectively. In addition, LATS1/2 promote apoptosis by the induction of proapoptotic genes, such as P53 and Bax, or by the down-regulation of antiapoptotic proteins, such as Bcl-2 and Bcl-X l [14] . Mutations in the LATS genes are rare, and a loss of function in either LATS1 or LATS2 leads to various malignant neoplasm such as leukemia [17] , breast cancer [18, 19] , astrocytoma [20] and soft tissue sarcoma [21] , but the expression level of LATS family members in squamous cancer of the cervix (SCC) remains unclear.
Presently, the importance of homology to the E6AP carboxyl terminus (HECT)-type E3s in crucial signaling pathways, which have been implicated in tumorigenesis, has attracted the attention of many researchers [22, 23] . Increasingly, data have suggested that the ubiquitin-mediated degradation of critical tumor suppressors by the HECT-type E3s plays a vital role in tumor formation [24] . ITCH (also known as atrophin1-interacting protein 4; AIP4) contains a Ca 2+ /lipidbinding (C2) domain involved in membrane targeting, four WW domains conferring substrate specificity and a HECTtype ligase domain that provides the catalytic E3 activity. ITCH also plays an important role in the regulation of protein stability [25, 26] and serves as the crucial regulator of differentiation in epithelial tissue development [27] . Although a number of ITCH substrates have been connected with tumorigenesis and chemosensitivity, including p63 [28, 29] , p73 [29] , cJun [30] and ErbB4 [31] , the roles of ITCH during tumorigenesis are yet to be defined.
In a previous study, we found that p63 expression was decreased or absent in SCC [13] . In this study, we aim to explore the subcellular localization and expression of ITCH and it alternate substrate, LATS1, in the different stages and grades of cervical dysplasia and SCC, which will illustrate the functions of ITCH and LATS1 during the malignant transformation of cervical cells.
Materials and Methods

Ethics Statement
A total of 110 archived formalin-fixed paraffin-embedded cervical specimens preserved between January 2007 and November 2011 were obtained from the Department of Pathology at Anhui Provincial Hospital, which is affiliated with Anhui Medical University, Hefei, China. The study was reviewed and approved by the ethical committee of Anhui Medical University, and written informed consent was obtained from all patients.
Patients and clinical samples
All paraffin-embedded cervical tissues were cut into 1 to 2 μm-thick sections for immunohistochemistry. Clinical stages were determined by two certified gynecologists according to a modified International Federation of Gynecology Obstetrics (FIGO) staging system for cervical cancer, which was published in 2000. The pathologic diagnosis of cancer tissues was evaluated according to the criteria recommended by at least two pathologists, according to the 2003 revised criteria suggested by the World Health Organization [reference]. The samples included 24 cases of normal cervical tissues, 20 cases of cervical intraepithelial neoplasia I (CIN I), 26 cases of cervical intraepithelial neoplasia II/III (CIN II/III) and 40 cases of SCC. The normal cervical tissues were obtained from patients who underwent a hysterectomy for reasons other than neoplasia of the cervix without a history of CIN or abnormal liquidbased cytological test (LCT) smears. The cervical neoplasm specimens were obtained from patients who underwent an operation or cervical biopsy. Patients with acute pelvic infection or who had received a cytology examination within six months, cervical therapy or preoperative treatment (such as radiotherapy and chemotherapy) were excluded. The cervical specimens were divided into four histological groups: Normal (N), CIN I, CIN II/III, SCC (I-IIa). All of the patients with SCC had been surgically treated with a wide excision of the primary tumor and a simultaneous classical radical uterine dissection together with the dissection of the regional lymph nodes.
Immunohistochemistry and Evaluation of Immunoreactivity
The tissue sections were deparaffinized in xylene for 10 min, fixed using 100% ethanol for 5 min, and then dehydrated with 95%, 85% and 75% ethanol. Endogenous peroxide activity was reduced with 3% hydrogen peroxide in methanol for 10 min at room temperature. The sections were washed twice with phosphate buffered saline (PBS) and incubated with the primary antibody overnight at 4°C. The sections were then washed twice with PBS and incubated with the corresponding secondary antibody for 30 min at 37°C. The sections were then rinsed with PBS and incubated for 2 min with high-sensitivity substrate diaminobenzidine (DAB). Finally, the slides were counterstained with 10% hematoxylin, and photographs were captured using a microscope with a digital camera. Normal cervical tissues were used as a positive control for LATS1 and cervical cancer cell line HeLa as a positive control for ITCH. Negative controls (i.e., the omission of primary antibodies) were included in each slide run, and all controls produced appropriate results.
Immunoreactivity was semiquantitatively evaluated based on staining intensity and distribution using the immunoreactive score: immunoreactive score= intensity score × proportion score. The intensity score was defined as 0, negative; 1, weak; 2, moderate; or 3, strong, and the proportion score was defined as 0, negative; 1, <10%; 2, 11～50%; 3, 51～80%; or 4, >80% positive cells. The total score ranged from 0 to 12. The immunoreactivity was divided to three levels on the basis of the final score: negative immunoreactivity was defined as a total score of 0, low immunoreactivity was defined as a total score of 1-4, and high immunoreactivity was defined as a total score >4 [32] . The stained tumor tissues were scored by two researchers blinded to the clinical patient data.
The ITCH (1:200) antibody was purchased from Abcam Biochemical (Cambridge, USA), LATS1 (1:50) antibody was purchased from SIGMA (Saint Louis, USA) and the secondary antibody was purchased from Santa Cruz Biotechnology (Santa Cruz, USA).
Statistical Analysis
All statistical analyses were performed using the statistical package SPSS (Chicago, USA), version 13. The association of the clinicopathological parameters with ITCH and LATS1 expression was estimated using the χ2-test, Fisher's exact test, or the Kruskal-Wallis H-test. The correlation between ITCH and LATS1 expression was analyzed using the χ2-test for a linear trend. A P-value <0.05 was considered statistically significant.
Results
Clinical and pathological characteristics of the patient specimens
A total of 110 specimens were analyzed. The main clinical characteristics of the patients are summarized in Table 1 .
Elevated ITCH expression and reduced LATS1 expression during cervical carcinogenesis
The expression levels and subcellular localizations of the ITCH protein were measured in paraffin-embedded normal cervical, CINs and SCC samples using immunohistochemical staining (Fig. 1) Statistical analysis showed that both the nuclear and cytoplasmic ITCH expression levels in SCC were significantly higher than those in normal cervical tissue (P<0.001). In the precancerous lesion, CINs tissues also exhibited immunoreactivity of ITCH in both the nucleus and cytoplasm, with the expression levels decreasing between those observed in the SCC and normal tissue (Fig. 2 A) . Membrane ITCH expression levels were low in the normal tissues and barely expressed in the SCC samples
The expression level and subcellular localization of the LATS1 protein were then explored by immunohistochemical staining using the same tissues as used for the ITCH protein. LATS1 protein is primarily localized within the membrane, but it is also expressed in the nucleus and the cytoplasm. The high membrane expression of LATS1 was found in 100% (24/ 24) of normal cervix, 100% (20/20) of CIN, 46.2% (12/26) of CIN II/III and 1.5% (1/40) of SCC tissues. Statistical analysis showed that the membrane expression of LATS1 levels in SCC was significantly lower than in normal cervical tissue (P=0.001). In the precancerous lesion, CIN tissues also displayed immunoreactivity of LATS1 in the membrane, with expression levels between those of SCC and normal tissue. Conversely, normal cervical tissue exhibited very low levels of cytoplasmic LATS1 expression, and SCC samples displayed low LATS1 expression; however, nuclear LATS1 expression levels were low in the normal tissues and scarcely expressed in SCC (Fig. 2 B) .
ITCH and LATS1 protein expression in SCC specimens
To better illustrate both ITCH and LATS1 protein expression in normal and SCC tissues, 12 cases of special cervical SCC specimens that contained both normal and cancer tissue in the same paraffin-embedded section were selected. Both nuclear and cytoplasmic ITCH expression levels in cancer tissue were significantly higher than in normal tissue (P=0.008 and P=0.019, respectively) and that ITCH expression in the membrane was low in normal tissue and almost negative in SCC (Figs. 3A and 3B) ; however, the LATS1 membrane expression in cancer tissue was significantly lower than in normal tissue (P=0.003), LATS1 expression in the cytoplasm was low in SCC specimens and nuclear LATS1 expression was negative in SCC specimens (Figs. 3C and 3D) .
Correlation between ITCH and LATS1 expression
Because LATS1 is a recently reported substrate of ITCH, the correlation between ITCH and LATS1 protein expression was analyzed in the cervical tissues. Serial sections were used to detect the expression of the two proteins in the same tissues. Because of the clearly elevated ITCH expression in the nucleus and cytoplasm of SCC specimens, and the noticeably reduced expression of LATS1 in the membrane of SCC specimens, the correlative analysis focused on the nuclear and cytoplasmic ITCH expression and the membrane LATS1 expression in the cervical tissues. The specimens that showed low ITCH expression and also displayed significant LATS1 staining; when ITCH expression was up-regulated, LATS1 expression was down-regulated (Fig 1) . The aberrant membrane staining of LATS1 was enhanced when the samples showed high nuclear or cytoplasm ITCH expression. This correlation could be found not only in normal cervical tissues but also in CINs and SCC (Fig. 1) . The association between the expression levels of Table 2 . The membrane expression level of LATS1 was inversely associated with ITCH nuclear and cytoplasm expression (r = -0.632 and -0.394, respectively).
Association of the clinical and pathological variables with the expression levels of LATS1 and ITCH
The relationship between the clinical pathological features in patients with SCC and the expression levels of LATS1 and ITCH is shown in Table 3 . No significant association was found between LATS1 and ITCH expression levels with patient age, lymph node invasion and differentiation grades of tumor cells in a total of 40 cervical squamous cell cancer cases; however, nuclear expression levels of ITCH were positively correlated with tumor size (P=0.046) and FIGO stage (P=0.036) in the SCC patients. The cytoplasmic level of ITCH was also positively correlated with tumor size (P=0.039) and FIGO stage (P=0.003), whereas the low membrane expression of LATS1 was significantly correlated with the clinical stage (P=0.036) and tumor size (P=0.023) ( Table  3) .
Discussion
It has been previously reported that the abnormal epithelial differentiation of the cervix contributes to the tumorigenesis of cervical cancer [13, 33] . p63, notch1, microRNAs, and ITCH are considered to be the most important regulators of differentiation [12, [33] [34] [35] . In the present study, the expression patterns of ITCH in the progression of SCC were investigated. ITCH belongs to the Nedd4-like family of E3 ubiquitin ligases and is characterized by a modular organization that includes a protein kinase C-related C2 domain at the Nterminus, four WW domains and a HECT ubiquitin protein ligase domain at the C-terminus [24] . Nedd4-like E3 ligases are critical for carcinogenesis, including the overexpression of Smurf2 in esophageal squamous cell carcinoma [36] in prostate and breast cancer [37] [38] [39] [40] [41] , Nedd4 in prostate and bladder cancer [42] [43] [44] [45] and Smurf1 in pancreatic cancer [46, 47] ; however, the association between ITCH and cancer remains unclear. ITCH-deficient mice develop a fatal disease that is characterized by constant itching of the skin and the development of severe inflammatory and immune diseases [48] . Recently, an emerging number of ITCH protein targets have been demonstrated to be important in tumorigenesis and chemosensitivity, such as p63, p73 and LATS1 [25, 29, [49] [50] [51] . It has been reported that knockdown of ITCH, using small interfering RNA (siRNA), can increase apoptosis upon treatment with chemotherapeutic drugs [52] . Indeed, ITCH is amplified and/or upregulated in several types of human malignancies, such as anaplastic thyroid carcinoma (ATC), papillary thyroid carcinoma, and papillary microcarcinoma [53] . Furthermore, knockdown of ITCH by siRNA significantly inhibits the growth of ITCH over-expressing cells, whereas the overexpression of ITCH promotes growth of ATC cell lines with relatively weak expression [54] . In medulloblastoma, ITCH disrupts Gli1 transcriptional activity by promoting its degradation, thereby improving the Gli1-dependent medulloblastoma growth, migration and invasion abilities [55, 56] . These data strongly suggest that ITCH may play a crucial role in tumorigenesis. In the present study, a gradual increased nuclear and cytoplasm expression of ITCH was observed during the tumorigenesis of SCC (from normal cervix, CINs to SCC) and the inverse correlation of nuclear and cytoplasm expression of ITCH with LATS1 membrane expression (one of tumor suppressors) in the corresponding cervical carcinoma tissues, which further identified the importance of ITCH in the process of cervical carcinogenesis. LATS1 plays a vital role in the Hippo-LATS pathway and regulates various biological processes, such as tumorigenesis, metastasis, stem cell differentiation and neural dendrite growth (12) (13) (14) . LATS1 is a serine/threonine kinase and potent tumor suppressor that is found to be down-regulated in many cancers. In this study of 110 clinical samples, decreased expression of LATS1 in the membrane was crucial to cervical cancer progression. Recently, ITCH was reported to be a unique binding partner and negative regulator of LATS1. It was shown that destabilizing LATS1 promotes the polyubiquitinationproteasome pathway. Additionally, it has been reported that ITCH demonstrates strong inhibitory effects on LATS1 downstream signaling to control cell proliferation and apoptotic function in a variety of cancer cell lines. Here, membrane expression of LATS1 was gradually reduced during the tumorigenesis of SCC (from normal cervix, CINs to SCC), suggesting that LATS1 might be downregulated by ITCH or/and other molecular factors.
The cytoplasmic, membrane and nuclear staining of both ITCH and LATS1 were studied because the subcellular localization of proteins is correlated with their function in cancer progression. A positive association between ITCH expression and both cervical carcinogenesis and carcinoma progression was obtained when we analyzed the immunoreactivity of ITCH in the nucleus and the cytoplasm. It is worth noting that the main localization of ITCH is in the nucleus of the cancer cells, suggesting that ITCH might be an important transcriptional factor that has been neglected by researchers. Nuclear and cytoplasmic expression of ITCH correlated with the tumor size (P<0.05 and P<0.05, respectively) and clinical stage (P<0.05 and P<0.05, respectively), suggesting that the increased expression of ITCH may contribute to tumor growth. An inverse association between LATS1 expression and cervical carcinogenesis as well as carcinoma progression was shown when we analyzed the immunoreactivity of LATS1 in the membrane. The data also showed that the low membrane expression of LATS1 was correlated with the tumor size (P<0.05) and clinical stage (P<0.05), indicating that the expression of LATS1 may inhibit tumor growth.
In summary, these data provide vigorous evidence that low LATS1 expression and high ITCH expression are frequently present in SCC. The decrease of LATS1 expression and increase of ITCH expression in SCC are significantly correlated with clinical stage and tumor size and are associated with the malignant transformation of cervical cancer. This study indicates that the abnormal expression levels of LATS1 and ITCH are important in the tumorigenesis of cervical tissues and that decreasing the expression of ITCH may serve as a novel therapeutic strategy for inhibiting the progression of precancerous neoplasm to cervical cancer.
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